A handful of new drugs and therapeutics recently received orphan drug status from the Food and Drug Administration, or FDA. It qualified their sponsors for various development incentives.
First on the list is ADS-5102, Adamas Pharmaceuticals' product candidate in the treatment of levodopa-induced dyskinesia associated with Parkinson's disease — a condition that currently has no FDA-approved treatment options. Adamas Pharmaceuticals is already conducting multiple phase III trials evaluating the effectiveness of ADS-5102 for this indication.
According to company CEO Gregory Went, "Adamas is committed to bringing new treatments to patients suffering with movement disorders related to neurological disorders. With positive data from our Phase II/III study, a pivotal Phase III program well underway, and 10 issued US patents, we are pleased with our ongoing momentum."